Fresenius | FRE - Des Atouts





Des Atouts Changement Date
Akzo Nobel EUR 16.13B 647M 2026-06
Alcon AG USD 31.1B 521M 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
BASF EUR 83.87B 2.1B 2026-06
Bayer EUR 107.29B 659M 2026-06
Beiersdorf EUR 12.76B 166M 2025-12
DaVita Healthcare Partners USD 17.71B 210.12M 2026-06
Demant DKK 40.03B 951M 2026-06
E.ON EUR 115.44B 1.78B 2026-06
Essilor EUR 65.06B 1.16B 2026-06
Fresenius EUR 41.84B 526M 2026-06
Fresenius Medical Care EUR 31.29B 174.35M 2026-06
Getinge SEK 57.37B 6.55B 2026-06
Givaudan CHF 11.86B 587M 2025-12
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
GN Store Nord DKK 29.55B 996M 2026-06
GRIFOLS EUR 20.09B 12M 2026-06
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Lonza CHF 18.97B 164M 2025-12
Merck EUR 52.69B 383M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Philips EUR 26.7B 565M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
RWE EUR 115.73B 1.04B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Smith & Nephew USD 11.01B 321M 2026-06